Vunakizumab for Hidradenitis Suppurativa: A New Biologic Therapy with Potential in Aesthetic Medicine
Recent clinical success with an IL-17 inhibitor highlights expanding therapeutic options for inflammatory skin conditions that aesthetic clinicians may encounter in consults.
Market context
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts in apocrine gland–rich areas such as the axillae, groin, and under breasts. It affects approximately 1% of the population, with significant impact on quality of life and often requiring multidisciplinary management [1]. The market for HS therapeutics has been dominated by adalimumab (the only FDA-approved biologic for HS), but recent clinical success with vunakizumab, an IL-17A inhibitor, offers a new mechanism of action [2].
Clinical evidence
A July 2026 case report in Frontiers in Immunology documented the use of vunakizumab in a 17-year-old with HS [2]. The report describes marked improvement after 8 weeks of treatment and no recurrence or significant adverse events during 10 months of follow-up. This is a single case report, not evidence of established efficacy or a practice-changing standard. It provides an early clinical signal that warrants controlled study.
Regulatory landscape
Vunakizumab is not FDA-approved for hidradenitis suppurativa. The case report describes use in China; it should not be interpreted as an indication for aesthetic clinicians to prescribe biologics. Suspected HS warrants appropriate evaluation and referral to dermatology or primary care.
Why this matters to clinic owners
1. Recognition supports appropriate referral. Chronic, painful lesions in intertriginous areas may warrant consideration of HS rather than being treated as a routine cosmetic concern. Diagnosis and management belong with qualified medical clinicians.
2. Emerging evidence needs careful framing. The vunakizumab report is one case. Clinics should avoid presenting it as an established HS treatment or promising outcomes; stronger clinical evidence and regulatory review would be needed.
3. Comorbidities may affect care coordination. HS can coexist with other inflammatory and metabolic conditions. Aesthetic teams should use appropriate history-taking and referral pathways rather than attempting to manage HS within aesthetic services.
4. Referral networks matter. Clear documentation and access to dermatology referral pathways can help ensure clients with possible HS reach clinicians experienced in its management.
What we’re watching
Further controlled studies of vunakizumab and other IL-17 inhibitors for HS will be needed to clarify efficacy, safety, and long-term outcomes. Clinicians should follow peer-reviewed evidence and relevant regulatory updates.
About Glowgau — A plug-and-play AI conversion layer for aesthetic and rejuvenation clinics: website, social, chat, and call — no contracts, no software to install, and zero patient data held by us (your clinic owns it, always). The AI front desk staff assistant is specialized in your clinic's services, protocols, and details to provide safe, informed responses and convert inquiries into qualified leads 24/7 — not replacing your front desk team, but backing them up after hours and during volume spikes. It chats, talks, and applies a global and Fitzpatrick scale facial assessment that turns inbound curiosity into booked consults. Built by a physician who saw the gap firsthand. What would your conversion rate look like if every inquiry — at any hour — had a clinician-grade intake waiting? glowgau.com
Rejuvenation Medicine Intel. by Glowgau. Rejuvnatia.intelligentia
References
- Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76-90. doi:10.1016/j.jaad.2019.02.067. PMID: 30872156.
- Zhang M, He M, Tang T. Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review. Front Immunol. 2026;17:1852135. doi:10.3389/fimmu.2026.1852135.